Christobel Selecky Sells 95,722 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 95,722 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $9.01, for a total value of $862,455.22. Following the completion of the sale, the director directly owned 32,173 shares in the company, valued at $289,878.73. This represents a 74.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christobel Selecky also recently made the following trade(s):

• On Tuesday, June 30th, Christobel Selecky sold 1,000 shares of ImmunityBio stock. The shares were sold at an average price of $9.00, for a total transaction of $9,000.00.

ImmunityBio Stock Performance

ImmunityBio stock opened at $9.44 on Friday. The company has a 50-day simple moving average of $7.68 and a 200-day simple moving average of $6.72. The firm has a market capitalization of $9.89 billion, a P/E ratio of -11.11 and a beta of 0.01. ImmunityBio, Inc. has a one year low of $1.95 and a one year high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. As a group, sell-side analysts forecast that ImmunityBio, Inc. will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On ImmunityBio

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of ImmunityBio by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after acquiring an additional 5,122,052 shares during the period. State Street Corp increased its stake in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after acquiring an additional 5,139,890 shares during the period. Geode Capital Management LLC increased its stake in shares of ImmunityBio by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after acquiring an additional 1,030,113 shares during the period. Heights Capital Management Inc. acquired a new position in shares of ImmunityBio during the third quarter valued at approximately $16,152,000. Finally, Goldman Sachs Group Inc. raised its holdings in ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after purchasing an additional 5,012,001 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

IBRX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a report on Tuesday, June 2nd. D. Boral Capital restated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Finally, BTIG Research reaffirmed a “buy” rating and set a $12.00 target price on shares of ImmunityBio in a research note on Thursday, May 21st. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ImmunityBio presently has an average rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.